drug · small molecule
trilaciclib
Marketedupdated 3mo agoby Pharmacosmos AS🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for small cell lung carcinoma and 10 investigational indications.
targets
Cyclin-dependent kinase 6Cyclin-dependent kinase 4
all catalysts(0)
nothing on the calendar yet
Trials studying trilaciclib
- phase2Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
- phase2Study of Trilaciclib and Lurbinectidin
- phase3Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- phase2the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
- phase2Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
- phase2Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
- phase2Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- phase4Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 25, 2031
~5.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Nov 13, 2040compositionUS 12168666
- Jul 23, 2039method-of-use (U-3504)US 11529352
- Dec 5, 2037method-of-use (U-3504)US 12527798
- Dec 30, 2034compositionUS 8598186
- Mar 14, 2034method-of-use (U-3081)US 10085992
- Mar 14, 2034method-of-use (U-3080)US 10966984
- Mar 14, 2034method-of-use (U-3679)US 11717523
- Mar 14, 2034method-of-use (U-3080)US 9487530
- Oct 25, 2031compositionUS 10189849
- Oct 25, 2031formulationUS 10189850
- Oct 25, 2031formulationUS 10927120
- Oct 25, 2031formulationUS 11040042
- Oct 25, 2031compositionUS 8598197
- Oct 25, 2031compositionUS 9957276
FDA exclusivities (1)
- Feb 12, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that